Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 5/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139867 | 0.79 | TPH1 (0.45) | CCNT1MKNK1MKNK2PTGDR | |
| SCHEMBL4148108 | 0.78 | FYN (0.41) | CCNT1FYNMKNK1MKNK2PTGDR | |
| SCHEMBL4139805 | 0.77 | FYN (0.56) | FYNPTGDR | |
| SCHEMBL4148649 | 0.75 | PTGDR (0.39) | CCNT1FYNMKNK1MKNK2PTGDR | |
| SCHEMBL4139796 | 0.74 | CYP1A2 (0.47) | KDRMKNK1MKNK2PTGDRGRIN2B | |
| SCHEMBL4152258 | 0.73 | PIM1 (0.52) | KDRMKNK1MKNK2PTGDR | |
| SCHEMBL4160480 | 0.72 | PDGFRB (0.50) | CCNT1KDRMKNK1MKNK2 | |
| SCHEMBL1943667 | 0.72 | FYN (0.72) | FYNMKNK1 | |
| SCHEMBL1943668 | 0.71 | FYN (0.46) | CCNT1KDRFYN | |
| SCHEMBL4143605 | 0.70 | HIF1A (0.47) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | CCNT1 3712/4885CDK9 587/4885KDR 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.